Home Cart Sign in  
Chemical Structure| 134221-52-6 Chemical Structure| 134221-52-6

Structure of 134221-52-6

Chemical Structure| 134221-52-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 134221-52-6 ]

CAS No. :134221-52-6
Formula : C7H7ClN2O3
M.W : 202.60
SMILES Code : O=CC1=C(OC)N=C(OC)N=C1Cl
MDL No. :MFCD22556259
InChI Key :KSUIGOHQLMJUSE-UHFFFAOYSA-N
Pubchem ID :10976550

Safety of [ 134221-52-6 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 134221-52-6 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 6
Fraction Csp3 0.29
Num. rotatable bonds 3
Num. H-bond acceptors 5.0
Num. H-bond donors 0.0
Molar Refractivity 45.41
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

61.31 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.88
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.24
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.96
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

-0.08
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

1.66
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.13

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.02
Solubility 1.93 mg/ml ; 0.00953 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.13
Solubility 1.52 mg/ml ; 0.00749 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-2.48
Solubility 0.674 mg/ml ; 0.00333 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.66 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.18

Application In Synthesis of [ 134221-52-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 134221-52-6 ]

[ 134221-52-6 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 6320-15-6 ]
  • [ 109-94-4 ]
  • [ 134221-52-6 ]
  • 2
  • [ 134221-52-6 ]
  • [ 134221-59-3 ]
  • 3
  • [ 67-56-1 ]
  • [ 114124-34-4 ]
  • [ 134221-52-6 ]
  • (1-Benzyl-2-ethyl-8-formyl-7-methoxy-5-oxo-1,2,3,5-tetrahydro-imidazo[1,2-c]pyrimidin-3-yl)-acetic acid methyl ester [ No CAS ]
  • 4
  • [ 64-17-5 ]
  • [ 114124-34-4 ]
  • [ 134221-52-6 ]
  • (1-Benzyl-2-ethyl-8-formyl-7-methoxy-5-oxo-1,2,3,5-tetrahydro-imidazo[1,2-c]pyrimidin-3-yl)-acetic acid ethyl ester [ No CAS ]
  • (1-Benzyl-7-ethoxy-2-ethyl-8-formyl-5-oxo-1,2,3,5-tetrahydro-imidazo[1,2-c]pyrimidin-3-yl)-acetic acid ethyl ester [ No CAS ]
  • 5
  • [ 129975-11-7 ]
  • [ 134221-52-6 ]
  • (E)-4-[Benzyl-(5-formyl-2,6-dimethoxy-pyrimidin-4-yl)-amino]-but-2-enoic acid ethyl ester [ No CAS ]
  • 7
  • [ 123-75-1 ]
  • [ 134221-52-6 ]
  • [ 202463-38-5 ]
  • 8
  • [ 110-89-4 ]
  • [ 134221-52-6 ]
  • [ 202463-40-9 ]
  • 9
  • [ 111-49-9 ]
  • [ 134221-52-6 ]
  • [ 202463-41-0 ]
  • 10
  • [ 496-15-1 ]
  • [ 134221-52-6 ]
  • [ 202463-42-1 ]
  • 11
  • [ 635-46-1 ]
  • [ 134221-52-6 ]
  • [ 202463-43-2 ]
  • 12
  • [ 134221-52-6 ]
  • [ 6872-06-6 ]
  • [ 202463-44-3 ]
  • 13
  • [ 134221-52-6 ]
  • [ 2450-71-7 ]
  • 2,4-Dimethoxy-6-(prop-2-ynylamino)pyrimidine-5-carbaldehyde [ No CAS ]
  • 2,6-Dimethoxy-N-(prop-2-ynyl)-5-[(prop-2-ynylimino)methyl]pyrimidin-4-amine [ No CAS ]
  • 14
  • [ 4394-85-8 ]
  • [ 42362-16-3 ]
  • [ 134221-52-6 ]
  • 15
  • [ 134221-52-6 ]
  • [ 98277-30-6 ]
  • 16
  • [ 134221-52-6 ]
  • [ 2465-59-0 ]
  • 17
  • [ 134221-52-6 ]
  • Methyl 2-(1-benzyl-8-formyl-7-methoxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidin-3-yl)acetate [ No CAS ]
  • 18
  • [ 134221-52-6 ]
  • 2,4-Dimethoxy-6-(prop-2-ynylamino)pyrimidine-5-carbaldehyde oxime [ No CAS ]
  • 19
  • [ 134221-52-6 ]
  • Methyl 2-(8-benzyl-2,4-dimethoxy-5,6,7,8-tetrahydropteridin-6-yl)acetate [ No CAS ]
  • 21
  • [ 134221-52-6 ]
  • Methyl 2-(1-benzyl-8-hydroxyiminomethyl-7-methoxy-5-oxo-1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidin-3-yl)acetate [ No CAS ]
  • 22
  • [ 134221-52-6 ]
  • Methyl 5-benzyl-7,9-dimethoxy-1,3,3a,4,5,9b-hexahydroisoxazolo[3',4':4,5]pyrido[2,3-d]pyrimidine-3-carboxylate [ No CAS ]
  • 23
  • [ 134221-52-6 ]
  • Methyl 2-(10-acetyl-5-benzyl-1,3-dimethoxy-5,6,7,10,11,11a-hexahydroisoxazolo[2,3-d]pyrimido[5,4-f][1,4]diazepin-7-yl)acetate [ No CAS ]
  • 24
  • [ 134221-52-6 ]
  • Methyl 2-(11-acetyl-5-benzyl-1,3-dimethoxy-5,6,7,10,11,11a-hexahydroisoxazolo[2,3-d]pyrimido[5,4-f]diazepin-7-yl)acetate [ No CAS ]
  • 25
  • [ 134221-52-6 ]
  • Dimethyl 5-benzyl-1,3-dimethoxy-7-(2-methoxy-2-oxoethyl)-5,6,7,11a-tetrahydroisoxazolo[2,3-d]pyrimido[5,4-f][1,4]diazepine-10,11-dicarboxylate [ No CAS ]
  • 26
  • [ 134221-52-6 ]
  • 5-Benzyl-1,3-dimethoxy-7-(2-methoxy-2-oxoethyl)-5,6,7,10,11,11a-hexahydroisoxazolo[2,3-d]pyrimido[5,4-f][1,4]diazepine-10,11-dicarboxylate [ No CAS ]
  • 27
  • [ 134221-52-6 ]
  • ((1R,10bS)-1-Benzenesulfonyl-6-benzyl-8,10-dimethoxy-1,2,4,5,6,10b-hexahydro-3-oxa-3a,6,7,9-tetraaza-benzo[e]azulen-4-yl)-acetic acid methyl ester [ No CAS ]
  • 28
  • [ 134221-52-6 ]
  • ((4S,10bS)-1-Benzenesulfonyl-6-benzyl-8,10-dimethoxy-1,2,4,5,6,10b-hexahydro-3-oxa-3a,6,7,9-tetraaza-benzo[e]azulen-4-yl)-acetic acid methyl ester [ No CAS ]
  • 29
  • [ 134221-52-6 ]
  • Methyl 2-(5-benzyl-1,3-dimethoxy-11-methyl-10,12-dioxo-6,7,9a,10,11,12,12a,12b-octahydro-5H-pyrimido-[5,4-f]pyrrolo[3',4':4,5]isoxazolo[2,3-d][1,4]diazepin-7-yl)acetate [ No CAS ]
  • 30
  • [ 134221-52-6 ]
  • [ 202463-45-4 ]
  • 31
  • [ 134221-52-6 ]
  • 6,8-dimethoxy-1,2,3,3a-tetrahydropyrrolo[1,2-e]pyrido[2,3-d]pyrimidin-4,4(5H)-dicarbonitrile [ No CAS ]
  • 32
  • [ 134221-52-6 ]
  • [ 202463-46-5 ]
  • 33
  • [ 134221-52-6 ]
  • 7,9-dimethoxy-2,3,4,4a,5,6-hexahydro-1H-pyrido[1,2-e]pyrido[2,3-d]pyrimidin-5,5-dicarbonitrile [ No CAS ]
  • 34
  • [ 134221-52-6 ]
  • 8,10-dimethoxy-1,2,3,4,5,5a-hexahydroazepino[1,2-e]pyrido[2,3-d]pyrimidin-6,6(7H)-dicarbonitrile [ No CAS ]
  • 35
  • [ 134221-52-6 ]
  • [ 202463-47-6 ]
 

Historical Records

Technical Information

Categories

Similar Product of
[ 134221-52-6 ]

Chemical Structure| 1391054-67-3

A1267751 [1391054-67-3]

4-Chloro-2,6-dimethoxy-5-pyrimidinecarboxaldehyde-13C

Reason: Stable Isotope

Related Functional Groups of
[ 134221-52-6 ]

Chlorides

Chemical Structure| 6320-15-6

A963559 [6320-15-6]

4-Chloro-2,6-dimethoxypyrimidine

Similarity: 0.80

Chemical Structure| 960299-06-3

A257880 [960299-06-3]

4-Chloro-6-methoxy-5-methylpyrimidine

Similarity: 0.79

Chemical Structure| 65269-18-3

A208437 [65269-18-3]

Ethyl 4-chloro-2-methoxypyrimidine-5-carboxylate

Similarity: 0.74

Chemical Structure| 26452-81-3

A142435 [26452-81-3]

4-Chloro-6-methoxypyrimidine

Similarity: 0.68

Chemical Structure| 51421-99-9

A119864 [51421-99-9]

4-Chloro-2-methoxypyrimidine

Similarity: 0.67

Aldehydes

Chemical Structure| 4558-59-2

A155534 [4558-59-2]

4,6-Dimethoxypyrimidine-5-carbaldehyde

Similarity: 0.65

Chemical Structure| 95652-80-5

A246766 [95652-80-5]

2-Chloro-6-methoxynicotinaldehyde

Similarity: 0.64

Chemical Structure| 90905-32-1

A115298 [90905-32-1]

2-Methoxypyrimidine-5-carbaldehyde

Similarity: 0.64

Chemical Structure| 5305-40-8

A224019 [5305-40-8]

4,6-Dichloropyrimidine-5-carbaldehyde

Similarity: 0.63

Chemical Structure| 14160-91-9

A149907 [14160-91-9]

4,6-Dichloro-2-methylpyrimidine-5-carbaldehyde

Similarity: 0.60

Ethers

Chemical Structure| 6320-15-6

A963559 [6320-15-6]

4-Chloro-2,6-dimethoxypyrimidine

Similarity: 0.80

Chemical Structure| 960299-06-3

A257880 [960299-06-3]

4-Chloro-6-methoxy-5-methylpyrimidine

Similarity: 0.79

Chemical Structure| 65269-18-3

A208437 [65269-18-3]

Ethyl 4-chloro-2-methoxypyrimidine-5-carboxylate

Similarity: 0.74

Chemical Structure| 26452-81-3

A142435 [26452-81-3]

4-Chloro-6-methoxypyrimidine

Similarity: 0.68

Chemical Structure| 51421-99-9

A119864 [51421-99-9]

4-Chloro-2-methoxypyrimidine

Similarity: 0.67

Related Parent Nucleus of
[ 134221-52-6 ]

Pyrimidines

Chemical Structure| 6320-15-6

A963559 [6320-15-6]

4-Chloro-2,6-dimethoxypyrimidine

Similarity: 0.80

Chemical Structure| 960299-06-3

A257880 [960299-06-3]

4-Chloro-6-methoxy-5-methylpyrimidine

Similarity: 0.79

Chemical Structure| 65269-18-3

A208437 [65269-18-3]

Ethyl 4-chloro-2-methoxypyrimidine-5-carboxylate

Similarity: 0.74

Chemical Structure| 26452-81-3

A142435 [26452-81-3]

4-Chloro-6-methoxypyrimidine

Similarity: 0.68

Chemical Structure| 51421-99-9

A119864 [51421-99-9]

4-Chloro-2-methoxypyrimidine

Similarity: 0.67